ARCHIVES

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

This article is from The Cancer Letter archive.

Vol. 25 No. 30 | July 30, 1999

Download PDF Visit The Full Archive

Related Articles

Advisors approve set-aside for alternative medicine “best case series.”

November 19, 2004

Group Chairmen Criticize NCI Budget Priorities

July 11, 2003

FDA Approves Abbott’s HER-2 DNA Probe Kit.

January 25, 2002

Stone(y) Silence Didn’t Save His Job; Niamd’s Rall Rumored as Top Choice As New NIH Director

December 20, 1974

NCI to Press FDA For Quicker Drug Approval, Relaxation Of Survival Impact Requirement

June 26, 1987

ASCO Annual Meeting: New Approaches For Treatment of Hematologic Malignancies

June 30, 2006